TITLE

Simvastatin reduced mortality and vascular events in diabetes mellitus: COMMENTARY

AUTHOR(S)
Barrett-Connor, Elizabeth
PUB. DATE
January 2004
SOURCE
ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article focuses on a study related to patients with diabetes mellitus, published in the 2003 issue of the journal "Lancet." Heart protection study participants were selected for having a high risk for cardiovascular disease, not for having high low-density lipoprotein cholesterol levels. The study adds weight to the mounting evidence that treating diabetes with a statin can reduce the risk for major cardiovascular events, even though the most common lipid abnormality in diabetes is a combination of low high-density lipoprotein and high triglyceride levels.
ACCESSION #
12104523

 

Related Articles

  • Should a statin be routinely prescribed for primary prevention of cardiovascular disease in diabetes mellitus? Hackam, Daniel G. // CMAJ: Canadian Medical Association Journal;10/12/2004, Vol. 171 Issue 8, p857 

    Presents a study on the use of statins in preventing cardiovascular disease (CVD) in patients with type 2 diabetes. Procedures of the study; Factors that should be considered by clinicians for those without CVD; Effects of statins on the patients.

  • For Your Heart: Add Statins. Harrar, SarĂ­; Stuart, Annie // Prevention;Nov2003, Vol. 55 Issue 11, p176 

    Discusses research on the use of cholesterol-lowering statins as therapy for diabetics. Impact of using statin on the risk of cardiovascular disease.

  • First-line treatment patterns and lipid target levels attainment in very high cardiovascular risk outpatients. Xanthopoulou, Ioanna; Davlouros, Periklis; Siahos, Simos; Perperis, Angelos; Evangelia, Zaharioglou; Alexopoulos, Dimitrios // Lipids in Health & Disease;2013, Vol. 12 Issue 1, p1 

    Objectives Previous studies have demonstrated gaps in achievement of low-density lipoproteincholesterol (LDL-C) goals among patients at very high cardiovascular risk. We aimed to investigate lipid treatment patterns, rates and predictors of lipid targets attainment, in such outpatients in an...

  • Doubt over statins in absence of CVD.  // GP: General Practitioner;7/9/2010, p4 

    The article discusses a medical care research report on the effectiveness of a cardiovascular agent Statin. It informs that the Great Britain's researchers showed that the agent does not reduces rates of mortality in patients having no cardiovascular disease. Kausik Ray and colleagues from...

  • Meta-analysis: Statin Therapy Does Not Alter the Association Between Low Levels of High-Density Lipoprotein Cholesterol and Increased Cardiovascular Risk. Jafri, Haseeb; Alsheikh-Ali, Alawi A.; Karas, Richard H. // Annals of Internal Medicine;12/21/2010, Vol. 153 Issue 12, p800 

    Background: Low levels of high-density lipoprotein cholesterol (HDL-C) are associated with an increased risk for myocardial infarction (MI). Although statins reduce the risk for MI, most cardiovascular events still occur despite statin treatment. Purpose: Using meta-analysis of large randomized,...

  • STATINS. Doyle, Matt // Pulse;5/24/2007, Vol. 67 Issue 20, p64 

    The article offers information about statins, along with its therapeutic use and side-effects. Statins are considered as the most omnipresent drugs used in modern medicine due to their mechanism of action causing upregulation of Low-density lipoprotein (LDL) receptors and reduction in levels of...

  • Statins reduce risk of major vascular events in low-risk individuals.  // Diabetes Digest;2012, Vol. 11 Issue 3, p178 

    The article reflects on study conducted to determine the effect of lowering Low Density Lipoprotein (LDL) cholesterol on the risk of major vascular events (MVEs) in individuals at low vascular risk and reveals that reduction in risk of MVE was approximately 11 per 1000 over 5 years.

  • Warning on Framingham in diabetes.  // Pulse;3/4/2009, Vol. 69 Issue 7, p12 

    The article presents a study on the use of Framingham score in assessing cardiovascular risk in diabetics, led by Hermione Price of Oxford University in Oxford, England. It is found that the use of tools would improperly exclude notable numbers of patients from treatment. Moreover, it states...

  • Gender Differences in Utilization of Effective Cardiovascular Secondary Prevention: A Cleveland Clinic Prevention Database Study. Cho, Leslie; Hoogwerf, Byron; Huang, Julie; Brennan, Danielle M.; Hazen, Stanley L. // Journal of Women's Health (15409996);May2008, Vol. 17 Issue 4, p515 

    Background: Previous studies have suggested that women with cardiovascular disease may receive less aggressive care than men. Using a large cardiology database from a tertiary referral center, we sought to determine if treatment differences still persist in the current era. Methods: We analyzed...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics